Skip to content

    Sun Pharma Advanced Research Company Limited

    SPARCMixed
    Healthcare·19 Dec 2024
    Management Summary

    SPARC held a general business update call, outlining a strategic pivot following the negative full results of its PROSEEK study. The company is now focusing its resources on two anchor assets, SCD-153 for autoimmune conditions and SBO-154, a novel MUC-1 ADC for oncology, with several clinical milestones targeted for FY26-FY27. Facing resource constraints, SPARC is actively pursuing short-term cash catalysts, including a potential Pediatric Rare Disease Voucher for Sezaby valued over 150 million USD and a CML program partnership, while also adjusting its operational structure with significant headcount reductions.

    Highlights

    7
    • PROSEEK study closed at 491 patients; full analysis confirmed interim negative trends.

    • Strategic pivot to an optimized portfolio focusing on SCD-153 (Alopecia Areata) and SBO-154 (MUC-1 ADC) as anchor assets.

    • SCD-153 Phase 1 completed successfully, with a Phase 1B study in Alopecia Areata patients to initiate in Q1 FY26.

    • SBO-154 pre-IND meeting with FDA showed broad agreement; IND filing anticipated by end of Q4 FY2025.

    • Company started the year with 15.2 million USD opening cash, relying on operating cash flow and debt, which may last until mid-Q1 next year.

    • Actively pursuing monetization opportunities including a potential Pediatric Rare Disease Voucher for Sezaby, valued over 150 million USD, with a court opinion expected Q4 FY25.

    • Headcount reduced from a planned FY2025 headcount of 400+ to 324 currently, with US headcount dropping from 37 to 7, reflecting a down-sizing of clinical development capability.

    Concerns

    1
    • Resource constraints and limited funding runway post-PROSEEK setback.

    What Changed4

    vs Q2 FY26

    Tone shiftGood → MixedGuidance items13 → 15 (+2)Risks discussed5 → 4 (-1)Q&A highlights0 → 3 (+3)

    Key financials

    Single quarter

    01 metrics
    1. 01Opening Cash15.2 mn USD

    Guidance & targets

    14
    CategoryTargetPriority
    Clinical Program
    SCD-153 Phase IB Study Initiation
    Q1 FY26
    High
    Clinical Program
    SCD-153 Phase IB Interim Readout
    Q1 FY27
    High
    Clinical Program
    SBO-154 Phase I Study Initiation
    Q1 FY26
    High
    Clinical Program
    Vibozilimod Atopic Dermatitis Topline Readout
    Q4 FY25
    High
    Clinical Program
    Vibozilimod Psoriasis Topline Readout
    Q1 FY26
    High
    Regulatory
    SBO-154 IND Filing
    end of Q4 FY2025
    High
    Regulatory
    PDP-716 CRL Response Completion
    2nd quarter of the next financial year
    Medium
    Regulatory
    PDP-716 Approval
    before the turn of FY26
    Medium
    Regulatory
    Sezaby PRV Court Opinion
    last quarter of this financial year
    Medium
    Regulatory
    Sezaby Orphan Drug Exclusivity Enforcement
    by the third quarter of this coming financial year
    Medium
    Partnership
    Vodobatinib CML Partner Identification
    end of this financial year
    Medium
    Headcount
    Current Headcount
    324
    High
    Headcount
    US Headcount
    7
    High
    Cash Flow
    Cash Runway
    mid Q1 next year
    Medium

    Risks & concerns

    4
    RiskSeverity

    Resource constraints and limited funding runway post-PROSEEK setback.

    The company started the year with 15.2 million USD in cash and is relying on operating cash flow and debt, which may only last until mid-Q1 next year, necessitating a focus on cash-generating catalysts.Management acknowledged

    high

    Regulatory uncertainty regarding the Pediatric Rare Disease Voucher (PRV) for Sezaby and enforcement of its orphan drug exclusivity.

    The PRV denial is under active litigation with a court opinion expected in Q4 FY25, and the enforcement of Sezaby's 7-year orphan drug exclusivity by the FDA is an ongoing process with some uncertainty.Management acknowledged

    medium

    Challenges in developing neurodegenerative disease programs, leading to a strategic shift away from this area.

    The reliability of animal models and viability of appropriate clinical trial designs were identified as key challenges that impacted the Vodobatinib program in Parkinson's disease, leading to most neurodegenerative programs being parked.Management acknowledged

    medium

    Regulatory issues with the API partner for PDP-716, causing a Complete Response Letter (CRL) and delaying approval.

    An external API manufacturer for PDP-716 had regulatory issues, resulting in a CRL; SPARC has since replaced the API source and made manufacturing changes to address this.Management acknowledged

    low

    Q&A highlights

    3

    “But if you come back to where we are in terms of operating cash flows and access to debt that we have, it will probably take us to the early part of next year. And then depending on where we reach with the short-term cash-generating opportunities, which we will have visibility by the end of this year. We will have to take a position in terms of how we plan to resource the continuing development of these programs, which we are committed to do.”

    This question directly addresses investor concerns about the company's financial runway and future funding strategy following the PROSEEK setback and potential delays in cash-generating milestones.

    asked by Vishal M

    3 min read7 chapters

    Detailed Narrative

    01

    PROSEEK Study Outcomes and Strategic Re-evaluation

    SPARC announced the full results of its PROSEEK study, which involved 491 patients, confirming the negative trends observed in the interim analysis. The long-term extension study with approximately 100 patients was also discontinued. This outcome prompted a significant strategic re-evaluation, leading the company to pivot its focus and optimize its portfolio towards more promising assets and a flexible business model.

    02

    Portfolio Optimization: Anchor Assets SCD-153 and SBO-154

    The company is narrowing its therapeutic area focus, designating SCD-153 and SBO-154 as anchor assets. Neurodegenerative disease programs, except for a few early platforms, have been parked due to challenges with animal models and clinical trial designs. The new focus areas are Oncology, emphasizing smart drug delivery and synthetic lethality, and Immunology, targeting safe topical alternatives for autoimmune conditions.

    03

    SCD-153 Program for Alopecia Areata Advances

    SCD-153, a topical pro-drug for autoimmune disorders like Alopecia Areata, has successfully completed its 'first in human' single ascending dose study, showing good tolerability up to the highest dose with no dose-limiting toxicities. Preclinical data demonstrated hair growth and reduction of CD8+ T cells in animal models. A Phase 1B study in Alopecia Areata patients in India is slated to begin in Q1 FY26, with an interim readout expected in Q1 FY27 and a global Phase IIB study targeted for Q4 FY27.

    04

    SBO-154: A Novel MUC-1 ADC in Oncology

    SBO-154 is a first-in-class humanized IgG1 antibody drug conjugate targeting the novel SEA domain of MUC-1, designed for advanced solid tumors. Preclinical studies showed high potency in MUC1-expressing cell lines and significant tumor reduction in xenograft models. Preliminary toxicology studies in cynomolgus monkeys demonstrated good tolerability up to 6 mg/Kg. SPARC anticipates filing the IND by the end of Q4 FY2025, with Phase I study initiation in Q1 FY26, targeting ER+ breast, lung, and ovarian cancers.

    05

    Pursuit of Short-Term Cash Catalysts

    To address resource constraints, SPARC is aggressively pursuing several short-term cash-generating opportunities. This includes seeking a Pediatric Rare Disease Voucher for Sezaby, potentially valued over 150 million USD, with a court opinion expected in Q4 FY25. The company is also working to enforce Sezaby's 7-year orphan drug exclusivity by Q3 FY25 and aims to identify a development and commercialization partner for Vodobatinib's CML program by the end of FY25.

    06

    Resource Management and Operational Adjustments

    SPARC initiated the year with 15.2 million USD in opening cash and is currently relying on operating cash flow and approved debt limits, which are projected to sustain operations until mid-Q1 next year. The company has undertaken significant headcount reductions, with current staff at 324 against a planned FY2025 headcount of over 400, and US headcount decreasing from 37 to 7, reflecting a strategic down-sizing of clinical development capabilities.

    07

    SCO-155 Partnership and New Business Model

    SPARC has adopted a more flexible business model, exemplified by the formation of Tiller Therapeutics, a NewCo with UCSF, for the SCO-155 program. SPARC will receive 55% of Tiller's initial shares. SCO-155, a PSMA-targeted small molecule drug conjugate, demonstrated strong in vitro efficacy and complete tumor regression in an in vivo xenograft model, paving the way for IND-enabling studies. This partnership model allows SPARC to advance promising programs without committing extensive internal resources.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.